Intellectual Properties – OncoLab Diagnostics GmbH

OncoLab Diagnostics has secured the following intellectual property rights:

Cancer Diagnosis and Prognosis

Publication No.: WO2020182517A1

A method of identifying an SCLC patient at risk of disease progression comprising determining the RNA-expression of at least one marker selected from a neuroendocrine marker and/or DLL3 in a fraction of a blood sample of said patient which blood fraction is enriched in circulating tumor cells (CTCs), wherein said at least one marker is indicative of the patient’s prognosis.

Method and kit for diagnosis of a cancerous disease, method for determining the reaction of a patient to the treatment for a cancerous disease medicament for the prophylaxis or treatment of a cancerous disease

Publication No.: WO2006018290, EP1786929

Diagnostic tests for circulating tumor cells in ovarian cancer.

Novel Tumor marker determination

Publication No.: WO2012123536, CA2830005, EP2686439, US20120238458

Diagnostic tests for circulating tumor cells in ovarian cancer.

Novel Tumor marker determination

Publication No.: EP2309273, US20140018259

Diagnostic tests for circulating tumor cells in breast, ovarian, endometrial and cervical cancer.

Composition and method for determination of CK19 expression

Publication No.: WO2007020081, EP1915461, US20140057265, CN101365800

Method for quantitative determination of CK19 mRNA-positive cells in a biological sample.

Multimarker panel

Publication No.: WO2012069659, CA2818976, EP2643477, US20130303400

Diagnostic test for early detection of ovarian cancer based on RNA biomarkers and RNA/protein biomarker models.

OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Straße 2, Objekt E
2700 Wiener Neustadt

AUSTRIA

+43 2622 32913

office@oncolab.at

legal notice | data protection